FDA mulls compounding for peptides previously flagged over safety risks BioSpace FDA Peptide Reclassification 2026: What Researchers Want The peptide conversation is shifting. Secretary RFK Jr. recently announced that the FDA plans to move 14 peptides from Category 2 back to Category 1 restoring FDA recognized status and making them BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification BPC 157 has a decades long safety record with zero deaths or hospitalizations. Yet, it's unapproved because the FDA process is too expensive and the business model doesn't allow for profit. Approved